Syndax announces compelling revuforj® (revumenib) and niktimvo™ (axatilimab-csfr) data accepted for presentation at ash 2025

– 12 revumenib and 11 axatilimab abstracts accepted, including 6 oral presentations, underscoring syndax's leadership in menin inhibition and csf-1r inhibition –
ASH Ratings Summary
ASH Quant Ranking